Recent clinical studies have shown that SGLT-2 inhibitors also have significant cardiovascular protective effects in non-diabetic CKD patients, especially in reducing the hospitalization rates for heart failure and the risk of cardiovascular death. Here, SLC5A2 is linked to heart failure.